Kazia Therapeutics share price has been driven by strong buying in their US-listed ADRs with the company’s market capitalisation moving from $75m to $200m since the Corporate Connect Research report was released. Corporate Connect biotech analyst Marc Sinatra updates the market post the ASX announcement by Kazia of further Paxalisib data.
For full details refer to the research report below or click here to download your copy.
[wonderplugin_pdf src=”https://www.sharecafe.com.au/wp-content/uploads/2020/11/Kazia-Therapeutics-Flash-Note-PII-GBM-PI-DIPG-Late-Interim-Results-SNO-Conference.pdf” width=”100%” height=”900px” style=”border:0;”]
